Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981759 · ClinicalTrials.gov registry record · Phase 4
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT01981759 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 58 participants.
The verdict
NCT01981759, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will examine DCS effects on memory consolidation and cognitive flexibility as possible mediators of DCS enhancement of CBT for delusions.
Interventions
- OTHER Placebo
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG D-Cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981759
The ClinicalTrials.gov registry entry for NCT01981759 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01981759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981759 about?
NCT01981759 is a clinical study titled "D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions". This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will...
What is the current status of trial NCT01981759?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2014-02. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01981759?
The interventions under investigation include: Placebo (OTHER), Cognitive Behavioral Therapy (BEHAVIORAL), D-Cycloserine (DRUG).
Who is sponsoring clinical trial NCT01981759?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.